盘后数据出炉。 今日（7月30日），A股市场走势分化。截至收盘，上证指数报3615.72点，上涨0.17%；深证成指报11203.03点，下跌 0.77%；创业板指报2367.68点，下跌1.62%。两市合计成交18442.79亿元，较上一交易日增加411.09亿元。 1. 两市主力资金净流出近530亿元 今日沪深两市主力资金开盘净流出140.23亿元，尾盘净流出15.26亿元，两市全天主力资金净流出529亿元。 | | | 沪深两市最近五个交易日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 净流入金额 开盘净流入 | 八炭史超碰 | 超大单净买入 | | 2025-7-30 | -529.00 | -140. 23 | -15.26 | -253. 30 | | 2025-7-29 | -272. 18 | -181.52 | 18. 05 | -136.96 | | 2025-7-28 | -112. 73 | -66. 20 | -2. 30 | -28.15 | | 2025-7-25 | -309. 84 | -137.84 ...

截至29日收盘数据显示，年内6只ETF涨幅超100%，其中港股通创新药ETF今年以来涨107.18%，位列年内涨幅榜第一。 | 其余代码 | 草金周称 | 最新净值(元) | 目增长率(%) | 最新净值日期 | 区间张跌幅(%) 01.02-07.29 | | --- | --- | --- | --- | --- | --- | | 159570 SZ | 汇添富国证港股通创新药etf | 1.9899 | 4.33 | 20250729 | 107.18 | | 520700 SH | 万家中证潜股通创新药etf | 1.8397 | 4 59 | 20250729 | 106.52 | | 520500 SH | 恒生新药 | 2.0370 | 4.36 | 20250729 | 106.40 | | 159567 SZ | 港股创新药etf | 1.9654 | 4.25 | 20250729 | 106.18 | | 513120 SH | 广发中证香港创新药(qdii-etf) | 1.4883 | 4 58 | 20250729 | 105.38 | | 513780 SH | 景顺长城中证潜 ...

证券时报·数据宝统计，7月30日共有16家公司公布2025年半年报，其中13家净利润同比增长，3家同比 下降，14家营业收入同比增长，2家同比下降，净利润和营业收入同时增长的公司有仕佳光子等12家， 净利润和营业收入均下降的有键邦股份等1家，业绩增幅翻倍的公司有5家，其中仕佳光子增幅最大，达 1712.00%。（数据宝） | 代码 | 简称 | 每股收益 | 净利润（万 | 净利润同比 | 营业收入（万 | 营业收入同比 | | --- | --- | --- | --- | --- | --- | --- | | | | （元） | 元） | （%） | 元） | （%） | | 688313 | 仕佳光 子 | 0.4793 | 21664.75 | 1712.00 | 99262.53 | 121.12 | | | 华康洁 | | | | | | | 301235 | 净 | 0.1900 | 1868.30 | 273.48 | 83491.15 | 50.73 | | 600078 | 澄星股 份 | 0.0280 | 1856.12 | 211.08 | 177611.77 | 9.85 | | ...

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a total revenue of 3.01 billion yuan for the first half of 2025, marking an increase of 247 million yuan compared to the same period last year, achieving a continuous growth for five years with a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders reached 700 million yuan, an increase of 71.57 million yuan from the same period last year, also achieving five consecutive years of growth with a year-on-year increase of 11.38% [1] - The company reported a net cash inflow from operating activities of 495 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stands at 13.01%, a decrease of 1.38 percentage points from the previous quarter [1] - The latest gross profit margin is 75.24%, an increase of 0.55 percentage points from the previous quarter, achieving two consecutive quarters of growth and a year-on-year increase of 2.74 percentage points [1] - The latest return on equity (ROE) is 9.13% [1] Earnings Per Share - The diluted earnings per share (EPS) is 0.69 yuan, an increase of 0.07 yuan compared to the same period last year, achieving five consecutive years of growth with a year-on-year increase of 11.29% [1] Asset Management - The latest total asset turnover ratio is 0.35 times [1] - The latest inventory turnover ratio is 1.06 times [1] Shareholder Structure - The number of shareholders is 43,600, with the top ten shareholders holding a total of 550 million shares, accounting for 54.16% of the total share capital [1] - The top shareholders include: 1. Xuzhou Enhua Investment Co., Ltd. - 31.5% 2. Sun Pengsheng - 4.85% 3. Yi Zengliang - 3.93% 4. Fu Ce - 3.93% 5. Yang Ziliang - 3.65% 6. Zhang Xu - 2.15% 7. Ma Wusheng - 1.22% 8. China Life Insurance Co., Ltd. - 1.11% 9. Agricultural Bank of China - 0.89% 10. National Social Security Fund - 0.84% [1]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a total revenue of 3.01 billion yuan for the first half of 2025, with a net profit attributable to shareholders of 700 million yuan [1] Financial Performance - The company's operating cash flow decreased by 127 million yuan compared to the same period last year, representing a year-on-year decline of 20.43% [1] - The latest asset-liability ratio stands at 13.01%, an increase of 0.87 percentage points from the same period last year [2] - The gross profit margin is reported at 75.24%, while the return on equity (ROE) is 9.13%, down by 0.20 percentage points year-on-year [3] - The diluted earnings per share are 0.69 yuan [4] - The total asset turnover ratio is 0.35 times, a decrease of 0.02 times compared to the same period last year, reflecting a year-on-year decline of 5.36% [4] - The inventory turnover ratio is 1.06 times, down by 0.22 times year-on-year, indicating a decline of 17.37% [4] Shareholder Structure - The number of shareholders is reported at 43,600, with the top ten shareholders holding a total of 550 million shares, accounting for 54.16% of the total share capital [4] - The largest shareholder, Xuzhou Enhua Investment Co., Ltd., holds 31.50% of the shares [4]

Core Viewpoint - Enhua Pharmaceutical (002262.SZ) reported its semi-annual results for 2025, highlighting significant institutional investment and changes in public fund holdings [1][2]. Institutional Holdings - As of July 29, 2025, 22 institutional investors disclosed holdings in Enhua Pharmaceutical, totaling 374 million shares, which represents 36.83% of the company's total equity [1]. - The top ten institutional investors collectively hold 36.56% of the shares, with a slight increase of 0.09 percentage points compared to the previous quarter [1]. Public Fund Holdings - Three public funds reduced their holdings compared to the previous quarter, with a total decrease of 0.42% [2]. - Twelve new public funds disclosed holdings in Enhua Pharmaceutical, including notable names such as Southern CSI 500 ETF and Dachen Active Growth Mixed A [2]. - Fifteen public funds that previously held shares did not disclose their holdings this quarter, including several healthcare-focused funds [2]. Social Security Fund - One new social security fund, the National Social Security Fund 406 Combination, disclosed its holdings in Enhua Pharmaceutical during this period [2]. Insurance Capital - One insurance company, China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 005L-CT001, increased its holdings by 0.2% compared to the previous period [2]. Foreign Investment - One foreign institution, Hong Kong Central Clearing Limited, did not disclose its holdings this quarter, indicating a potential shift in foreign investment interest [3].

Group 1: Company News - The State-owned Assets Supervision and Administration Commission (SASAC) announced the establishment of China Changan Automobile Group Co., Ltd., marking the total number of state-owned enterprises under SASAC to 100 [4] - WuXi AppTec announced an adjustment to its share repurchase plan, raising the maximum repurchase price from 90.72 yuan to 114.15 yuan per share [6] - Shijia Photon reported a significant increase in net profit for the first half of 2025, achieving 217 million yuan, a year-on-year growth of 1712%, driven by the rapid growth of the AI market [7] - Time Space Technology announced the termination of its control change planning, stating that it will not adversely affect the company's operations or financial status [7] - Quzhou Development is planning to issue shares to acquire assets and raise matching funds, with a suspension of trading expected for no more than 10 trading days [8] - Huqin Technology plans to acquire 12 million shares of Crystal Integrated Circuit for 1.993 billion yuan, aiming to enhance resource integration and strategic investment [8] - Ancar Detection announced a potential change in its controlling shareholder, leading to a suspension of trading for up to 2 trading days [8] Group 2: Industry News - The National Health Commission and other authorities introduced a nationwide parenting subsidy system, which is expected to impact sectors such as dairy products, maternal and infant chains, and postpartum care services positively [9] - The China Photovoltaic Industry Association clarified misinformation regarding the photovoltaic industry's competition, emphasizing a commitment to market-oriented principles [4] - The Ministry of Finance reported a decline in revenue and profit for state-owned enterprises in the first half of 2025, with total revenue at 4.075 trillion yuan, down 0.2% year-on-year [5]

Group 1 - Novo Nordisk has lowered its full-year financial guidance for 2025, expecting sales growth of 8% to 14% at constant exchange rates, down from a previous forecast of 13% to 21% [1] - The downward revision is attributed to lower growth expectations for Wegovy in the U.S. obesity market and Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration rates for Wegovy in some international markets [1] - This reflects a trend of rational return in the GLP-1 sector, indicating that even leading companies face challenges in sustaining high-speed expansion amid high bases and intense market competition [1] Group 2 - Enhua Pharmaceutical reported a net profit of approximately 700 million yuan for the first half of 2025, an increase of 11.38% year-on-year, with total revenue reaching 3.01 billion yuan, up 8.93% [2][3] - The company demonstrated steady performance in the pain relief and anesthetic sectors, maintaining a solid market position despite overall pressures in the pharmaceutical industry [2] Group 3 - Changchun High-tech's subsidiary has received FDA approval for its innovative drug, Amlodipine Besylate Oral Solution Lyophilized Powder, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [3] - This approval enhances the company's product portfolio in the U.S. market and strengthens its competitive position in the pharmaceutical sector [3] - The product is a modified innovative drug that reduces blood pressure and minimizes the risk of cardiovascular events [3] Group 4 - Zhixiang Jintai has received clinical trial approval for its investigational product, SLEWEMI Monoclonal Antibody Injection, for passive immunity in children and adolescents exposed to suspected rabies virus [3] - This product is the world's first dual-specific antibody for rabies passive immunity, developed in accordance with WHO recommendations for antibody development [3] - The approval highlights the company's capabilities in international registration and the development of modified drugs [3]

Group 1 - Novo Nordisk has lowered its full-year financial guidance for 2025, expecting sales growth of 8% to 14% at constant exchange rates, down from a previous forecast of 13% to 21% [1] - The downward revision is attributed to lower growth expectations for Wegovy in the U.S. obesity market and Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration of Wegovy in certain international markets [1] - This adjustment reflects a trend of rational return in the GLP-1 sector, indicating that even leading companies face challenges in sustaining high-speed expansion amid high bases and intense market competition [1] Group 2 - Enhua Pharmaceutical reported a net profit of approximately 700 million yuan for the first half of 2025, an increase of 11.38% year-on-year, with total revenue reaching 3.01 billion yuan, up 8.93% [2] - The company's performance demonstrates steady growth in a challenging pharmaceutical industry, highlighting its solid market position in analgesics and psychiatric drugs [2] Group 3 - Changchun High-tech announced that its subsidiary has received FDA approval for the freeze-dried powder of Amlodipine Besylate oral solution, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [3] - This product approval enhances the company's product portfolio in the U.S. market and strengthens its competitive position in the pharmaceutical sector [3] Group 4 - Zhixiang Jintai has received approval for clinical trials of its investigational product, Sluveimi Monoclonal Antibody Injection, for passive immunity in children and adolescents suspected of rabies virus exposure [4] - This product is the world's first dual-specific antibody for rabies passive immunity, indicating the company's innovative capabilities in developing biopharmaceuticals [4]

Core Insights - The company reported a continuous growth in operating performance for the first half of 2025, achieving a revenue of 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% from the previous year [2] - The company specializes in the research and production of central nervous system drugs, with 60 approved new drug formulations and a market share leading in 29 products nationwide [2] Financial Performance - Revenue for the first half of 2025 reached 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [2] - Net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [2] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase from the previous year [2] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of approximately 395 million yuan, representing a 23.97% increase year-on-year [2] - There are currently 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - The company has signed a Pre-A round preferred stock purchase agreement with San Sheng Pharmaceutical, gaining priority negotiation rights for certain in-development drugs [3] Collaborations and Partnerships - The company has entered into a commercial cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. for the market development of its Oxycodone tablets [3] - The NHL35700 drug, introduced from Denmark, has completed Phase II clinical trials and is set to enter Phase III trials [3] - The Protollin project, developed in collaboration with Harvard Medical School and Tianjing Biotech, has successfully completed Phase I clinical trials in the U.S. and is moving to Phase II trials [3]